Evidence map›Paper›PMID 32569927›Full record

ArticleLeukemia research2020

Evolution of clonal dynamics and differential response to targeted therapy in a case of systemic mastocytosis with associated myelodysplastic syndrome.

Hyun Don Yun, Marie Lue Antony, Michael A Linden, Klara E Noble-Orcutt, Craig E Eckfeldt, Celalettin Ustun, Andrew C Nelson, Zohar Sachs

Abstract readCase ReportsLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hyun Don YunDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States; Division of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University, Chicago, IL, United States.
Marie Lue AntonyDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
Michael A LindenDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States.
Klara E Noble-OrcuttDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
Craig E EckfeldtDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Celalettin UstunDivision of Hematology, Oncology and Cell Therapy, Department of Medicine, Rush University, Chicago, IL, United States.
Andrew C NelsonDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States.
Zohar SachsDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, United States; Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States. Electronic address: sachs038@umn.edu.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
TRAINING IN HEMOGLOBIN &CELL MEMBRANE RESEARCHT32HL007062 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller, Gregory M Vercellotti · 1985 to 2026
$10.3M
UNIVERSITY OF MINNESOTA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UMN CTSI)UL1RR033183 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$8.9M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2RR033182 · NCRR · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2011 to 2011
$1.4M
HSRD VA SDR 16-195NCATS NIH HHS UL1 TR002494NCI NIH HHS P30 CA077598NCRR NIH HHS KL2 RR033182NCRR NIH HHS UL1 RR033183NHLBI NIH HHS T32 HL007062
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Molecular Targeted TherapyAntineoplastic AgentsClone CellsDioxygenasesDNA-Binding ProteinsDNA Mutational AnalysisFemaleHumansMastocytosis, SystemicMiddle AgedMyelodysplastic SyndromesProto-Oncogene ProteinsProto-Oncogene Proteins c-kitRepressor ProteinsAntineoplastic AgentsASXL1 protein, humanDioxygenasesDNA-Binding ProteinsKIT protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins c-kitRepressor ProteinsTET2 protein, human

Identifiers

PMID32569927
PMCPMC7685094

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.